Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 2:45 PM ET. The conference will be held virtually, and a live webcast will be available on the company's website. Deciphera focuses on developing new medicines for cancer treatment, including QINLOCK®, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST), also approved in Australia, Canada, China, and Hong Kong.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19^th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, China, and Hong Kong. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005147/en/

Investor Relations:

Jen Robinson

Deciphera Pharmaceuticals, Inc.

jrobinson@deciphera.com

781-906-1112

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What is the date and time of Deciphera Pharmaceuticals' participation in the Morgan Stanley Global Healthcare Conference?

Deciphera Pharmaceuticals will participate in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 2:45 PM ET.

How can I view the webcast of Deciphera Pharmaceuticals' conference participation?

The live webcast of Deciphera Pharmaceuticals' participation can be accessed on the 'Events and Presentations' page in the 'Investors' section of their website.

What is QINLOCK® and its significance for Deciphera Pharmaceuticals?

QINLOCK® is Deciphera Pharmaceuticals' FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST).

Where is QINLOCK® approved besides the United States?

QINLOCK® is also approved in Australia, Canada, China, and Hong Kong.